国际肿瘤学杂志

国际肿瘤学杂志 ›› 2016, Vol. 43 ›› Issue (4): 309-311.doi: 10.3760/cma.j.issn.1673422X.2016.04.019

• 综述 • 上一篇    下一篇

乳腺癌的靶向治疗

张程,张正权,符德元   

  1. 225001 扬州大学临床医学院苏北人民医院甲状腺乳腺外科
  • 出版日期:2016-04-08 发布日期:2016-03-02
  • 通讯作者: 符德元，Email：fdy1003@163.com E-mail:fdy1003@163.com
  • 基金资助:

    国家自然科学基金（81172508）

Targeted therapy of breast cancer

Zhang Cheng, Zhang Zhengquan, Fu Deyuan   

  1. Department of Thyroid and Breast Surgery, Subei People′s Hospital of Yangzhou University, Yangzhou 225001, China
  • Online:2016-04-08 Published:2016-03-02
  • Contact: Fu Deyuan E-mail:fdy1003@163.com
  • Supported by:

    National Natural Science Foundation of China (81172508)

PDF

1273

摘要： 乳腺癌靶向治疗基于分子分型为乳腺癌患者提供了一个有效和个性化治疗的选择。目前用于乳腺癌靶向治疗的药物包主要括以人表皮生长因子受体2（HER2）为靶点的药物曲妥珠单抗、帕妥珠单抗、拉帕替尼、TDM1和以血管内皮生长因子（VEGF）为靶点的贝伐珠单抗以及以雷帕霉素靶蛋白（mTOR）为靶点的依维莫司，多项研究表明靶向治疗联合化疗能显著提高患者的无进展生存期及总生存时间。

关键词: 乳腺肿瘤, 分子靶向治疗

Abstract: Targeted therapies of breast cancer offer a possibility of effective and individualized therapy based on the molecular profile of the tumor. Currently there are three main types of targeted therapeutic drugs for breast cancer, the first category is the monoclonal antibody against the human epidermal growth factor receptor 2 (HER2) including trastuzumab, pertuzumab, lapatinib, TDM1. The second is targeting VEGF such as bevacizumab. The last one everolimus is a mammalian target of rapamycin (mTOR) inhibitors. A number of trials suggest that the addition of targeted therapy to chemotherapy or endocrine therapy significantly improved PFS and OS in patients with breast cancer.

Key words: Breast neoplasms, Molecular targeted therapy